Oropharyngeal cancer epidemic and human papillomavirus

Emerging Infectious Diseases

Volumn 16, Issue 11, 2010, Pages 1671-1677

  Ramqvist, Torbjörn ^a   Dalianis, Tina ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN E6; PROTEIN E7; PROTEIN P16; PROTEIN P53; VIRUS DNA; WART VIRUS VACCINE;

ALCOHOL CONSUMPTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RESEARCH; CANCER SURVIVAL; DNA SEQUENCE; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; INCIDENCE; JAW OSTEONECROSIS; OROPHARYNX CANCER; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RISK FACTOR; SEXUAL BEHAVIOR; SMOKING; SPEECH DISORDER; SQUAMOUS CELL CARCINOMA; TONSIL CANCER; VERRUCA VULGARIS; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; EPIDEMICS; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TIME FACTORS;

EID: 77958610293     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1611.100452     Document Type: Article

References (40)

1. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11,16, and 18) L1 virus-like particle vaccine in young women: a randomiseddouble-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-8.DOI: 10.1016/S1470-2045(05)70101-7
2. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in youngwomen. J Natl Cancer Inst. 2010;102:325-39.DOI: 10.1093/jnci/djp534
3. Zur Hausen H. Infections causing human cancer. Weinheim (Germany):Wiley-VCH Verlag; 2006. p. 145-243.
4. Syrjänen S. Human papillomavirus (HPV) in head and neckcancer. J Clin Virol. 2005;32(Suppl 1):S59-66.DOI: 10.1016/j.jcv.2004.11.017
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin. 2005;55:74-108.DOI: 10.3322/canjclin.55.2.74
6. Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P, Lefebvre JL. Cancer of the oropharynx. Crit Rev Oncol Hematol. 2002;41:107-22.DOI: 10.1016/S1040-8428(01)00129-9
7. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst.2000; 92:709-20.DOI: 10.1093/jnci/92.9.709
8. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates,risk of relapse, and survival. Int J Cancer. 2000; 89:300-4.DOI:10.1002/1097-0215(20000520)89:3<300::AID-IJC14>3.0.CO;2-G
9. Dahlstrand HM, Dalianis T. Presence and influence of human papillomaviruses(HPV) in tonsillar cancer. Adv Cancer Res. 2005;93:59-89.DOI: 10.1016/S0065-230X(05)93002-9
10. World Health Organization. IARC monographs on the evaluation of carcinogenic risk to humans. Volume 90. Human papillomaviruses.Lyon (France): International Agency for Research on Cancer; 2007.
11. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidencein relation to smoking prevalence: an emerging epidemic ofhuman papillomavirus-associated cancers? Cancer. 2007;110:1429-35.DOI: 10.1002/cncr.22963
12. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, et al. Human papillomavirus as a risk factorfor the increase in incidence of tonsillar cancer. Int J Cancer.2006;119:2620-3.DOI: 10.1002/ijc.22177
13. Lindquist D, Romanitan M, Hammarstedt L, Nasman A, Dahlstrand H, Lindholm J, et al. Human papillomavirus is a favourable prognosticfactor in tonsillar cancer and its oncogenic role is supportedby the expression of E6 and E7. Mol Oncol. 2007;1:350-5.DOI:10.1016/j.molonc.2007.08.005
14. Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M, et al. Human papillomavirus type 16 is episomal anda high viral load may be correlated to better prognosis in tonsillarcancer. Int J Cancer. 2002;102:152-8.DOI: 10.1002/ijc.10669
15. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccinesand the potential prevention of noncervical cancers in bothmen and women. Cancer. 2008;113(Suppl):3036-46.DOI: 10.1002/cncr.23764
16. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients withoropharyngeal cancer. N Engl J Med. 2010;363:24-35.DOI:10.1056/NEJMoa0912217
17. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associatedhead and neck cancer: a virus-related cancer epidemic. Lancet Oncol.2010;11:781-9.DOI: 10.1016/S1470-2045(10)70017-6
18. Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. Incidence of human papillomavirus (HPV) positive tonsillarcarcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?Int J Cancer. 2009;125:362-6.DOI: 10.1002/ijc.24339
19. Attner P, Du J, Nasman A, Hammarstedt L, Ramqvist T, Lindholm J, et al. The role of human papillomavirus in the increased incidenceof base of tongue cancer. Int J Cancer. 2010;126:2879-84.
20. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, LorenzatoM, et al. Hybrid Capture II-based human papillomavirus detection,a sensitive test to detect in routine high-grade cervical lesions: apreliminary study on 1518 women. Br J Cancer. 1999;80:1306-11.DOI: 10.1038/sj.bjc.6690523
21. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongatedat their 3′ ends with adjacent highly conserved sequencesimproves human papillomavirus detection by PCR. J Gen Virol.1995;76:1057-62.DOI: 10.1099/0022-1317-76-4-1057
22. Tieben LM, ter Schegget J, Minnaar RP, Bouwes Bavinck JN, Berkhout RJ, Vermeer BJ, et al. Detection of cutaneous and genital HPVtypes in clinical samples by PCR using consensus primers. J VirolMethods. 1993;42:265-79.DOI: 10.1016/0166-0934(93)90038-S
23. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blotanalysis enables rapid and high-throughput identifi cation of humanpapillomavirus genotypes. J Clin Microbiol. 2002; 40:779-87.DOI:10.1128/JCM.40.3.779-787.2002
24. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27human papillomavirus types by using L1 consensus PCR productsby a single-hybridization, reverse line blot detection method. J ClinMicrobiol. 1998;36:3020-7.
25. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses.J Clin Microbiol. 2006;44:504-12.DOI: 10.1128/JCM.44.2.504-512. 2006
26. Mellin Dahlstrand H, Lindquist D, Bjornestal L, Ohlsson A, DalianisT, Munck-Wikland E, et al. P16(INK4a) correlates to human papillomaviruspresence, response to radiotherapy and clinical outcomein tonsillar carcinoma. Anticancer Res. 2005; 25(6C):4375-83.
27. Singhi AD, Westra WH. Comparison of human papillomavirus insitu hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on aprospective clinical experience. Cancer. 2010;116:2166-73.
28. Koskinen WJ, Chen RW, Leivo I, Makitie A, Back L, Kontio R, et al. Prevalence and physical status of human papillomavirus in squamouscell carcinomas of the head and neck. Int J Cancer. 2003; 107:401-6.DOI: 10.1002/ijc.11381
29. Mellin H, Friesland S, Auer G, Dalianis T, Munck-Wikland E. Humanpapillomavirus and DNA ploidy in tonsillar cancer-correlationto prognosis. Anticancer Res. 2003;23(3C):2821-8.
30. Dahlgren L, Mellin H, Wangsa D, Heselmeyer-Haddad K, BjornestalL, Lindholm J, et al. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances inhuman papillomavirus-positive and -negative tumors. Int J Cancer.2003;107:244-9.DOI: 10.1002/ijc.11371
31. Braakhuis BJ, Visser O, Leemans CR. Oral and oropharyngeal cancerin the Netherlands between 1989 and 2006: increasing incidence,but not in young adults. Oral Oncol. 2009;45:e85-9.DOI: 10.1016/j.oraloncology.2009.03.010
32. Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G, Macpherson LM. Incidence of oral and oropharyngeal cancer in United Kingdom(1990-1999)-recent trends and regional variation. Oral Oncol.2006;42:586-92.DOI: 10.1016/j.oraloncology.2005.10.018
33. Robinson KL, Macfarlane GJ. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing? Oral Oncol.2003;39:31-6.DOI: 10.1016/S1368-8375(02)00014-3
34. Hammarstedt L, Dahlstrand H, Lindquist D, Onelov L, Ryott M, Luo J, et al. The incidence of tonsillar cancer in Swedenis increasing. Acta Otolaryngol. 2007;127:988-92.DOI:10.1080/00016480601110170
35. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidencetrends for human papillomavirus-related and -unrelatedoral squamous cell carcinomas in the United States. J Clin Oncol.2008; 26:612-9.DOI: 10.1200/JCO.2007.14.1713
36. Syrjänen S. HPV infections and tonsillar carcinoma. J Clin Pathol.2004; 57:449-55.DOI: 10.1136/jcp.2003.008656
37. Anaya-Saavedra G, Ramirez-Amador V, Irigoyen-Camacho ME, Garcia-Cuellar CM, Guido-Jimenez M, Mendez-Martinez R, et al. High association of human papillomavirus infection with oral cancer:a case-control study. Arch Med Res. 2008; 39:189-97.DOI:10.1016/j.arcmed.2007.08.003
38. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oralsexual behaviors associated with prevalent oral human papillomavirusinfection. J Infect Dis. 2009;199:1263-9.DOI: 10.1086/597755
39. Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, et al. Immune response during therapy with cisplatin or radiationfor human papillomavirus-related head and neck cancer. ArchOtolaryngol Head Neck Surg. 2009;135:1137-46.DOI: 10.1001/archoto.2009.159
40. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectivenessof human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14:244-51.DOI: 10.3201/eid1402.070499